Atomwise

Atomwise is a pioneering biotechnology company that leverages artificial intelligence to transform the landscape of small-molecule drug discovery. Founded in 2012, the company utilizes its proprietary AtomNet® platform, which applies deep learning—specifically convolutional neural networks—to predict the binding affinity of molecules to protein targets. By replacing traditional, time-consuming physical screening with high-speed virtual screening, Atomwise aims to significantly reduce the cost and duration of developing new life-saving medicines.

To become one of the most prolific and diverse life science research groups in the world, leveraging AI to discover better medicines and improve the lives of billions of people.

• First company to commercialize deep neural networks for structure-based small-molecule drug discovery
• Virtually screened billions of compounds across hundreds of unique disease targets
• Supported hundreds of academic research collaborations globally
• Backed by prominent investors including Y Combinator, B Capital Group, and Tencent

Sources

• Official Atomwise Website
• Crunchbase Profile